Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

Study of Cases and Controls on Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01525199

Acronym

IDENTIFY

Enrollment

450

Registered

2012-02-02

Start date

2012-05-31

Completion date

2013-11-30

Last updated

2014-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer, Stage IIIB/IV

Keywords

Non-Small Cell Lung Cancer,, Epidermal Growth Factor Receptor mutation,, Lung cancer,, Lung adenocarcinoma

Brief summary

The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.

Detailed description

Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV. * Patients under 1st line treatment against lung adenocarcinoma.

Exclusion criteria

* Patients not having the information required by the protocol.

Design outcomes

Primary

Measure	Time frame
Disease free survival	12 months after the diagnosis of advanced disease
Overall Survival	12 months after the diagnosis of advanced disease
Number of hospitalizations	12 months after the diagnosis of advanced disease

Countries

Argentina

Outcome results